Bayer: Takeover in the USA – new cell and gene therapies

Bayer is stepping up its activities in the pharmaceutical sector with a billion-dollar takeover: the Leverkusen-based company is taking over Asklepios BioPharmaceutical The company specializes in the research, development and production of gene therapies in various therapeutic areas, Bayer said on Monday. The Asklepios BioPharmaceutical portfolio includes therapy candidates for the treatment of neuromuscular, cardiovascular and metabolic diseases as well as diseases of the central nervous system.

Bayer pays a total of up to $ 4 billion for the company – half of the amount upfront, the other half is performance-related and up to three-quarters could be incurred within the next five years. “With this transaction, Bayer acquires the full rights to the therapy platform from AskBio, including a broad-based, patented portfolio and a subsidiary for process development and production in the field of adeno-associated viruses (AAV) -based gene therapies, which is also active in the field of contract manufacturing ”, So the DAX group.

The group expects the takeover to be completed in the current quarter and thus this year.

“It is part of our strategy to develop new therapy platforms, including in the area of ​​cell and gene therapies,” says Stefan Oelrich, Member of the Board of Management of Bayer AG and Head of the Pharmaceuticals Division. “As an emerging company in the field of gene therapies, AskBio’s expertise and portfolio will support us in establishing highly innovative treatment options for patients and strengthen our portfolio,” said the manager.

Related Articles

Back to top button